Heat shock protein 90 as a molecular target for cancer therapeutics

Baselga, 1998, Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts, Cancer Res., 58, 2825

Basso, 2002, Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2, Oncogene, 21, 1159, 10.1038/sj.onc.1205184

Blagosklonny, 2001, The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy, Leukemia, 15, 1537, 10.1038/sj.leu.2402257

Connell, 2001, The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins, Nat. Cell Biol., 3, 93, 10.1038/35050618

Csermely, 1993, ATP induces a conformational change of the 90-kDa heat shock protein (hsp90), J. Biol. Chem., 268, 1901, 10.1016/S0021-9258(18)53939-9

Gnarra, 1994, Mutations of the VHL tumour suppressor gene in renal carcinoma, Nat. Genet., 7, 85, 10.1038/ng0594-85

Gorre, 2002, BCR-ABL point mutants isolated from patients with STI571-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90, Blood, 100, 3041, 10.1182/blood-2002-05-1361

Gradin, 1996, Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor, Mol. Cell. Biol., 16, 5221, 10.1128/MCB.16.10.5221

Grenert, 1997, The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation, J. Biol. Chem., 272, 23843, 10.1074/jbc.272.38.23843

Grenert, 1999, The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes, J. Biol. Chem., 274, 17525, 10.1074/jbc.274.25.17525

Harris, 2002, Hypoxia—a key regulatory factor in tumor growth, Nat. Rev. Cancer, 2, 38, 10.1038/nrc704

Hernandez, 2002, The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex, J. Biol. Chem., 277, 38294, 10.1074/jbc.M206566200

Hur, 2002, Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol, Mol. Pharmacol., 62, 975, 10.1124/mol.62.5.975

Isaacs, 2002, Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway, J. Biol. Chem., 277, 29936, 10.1074/jbc.M204733200

Kelland, 1999, DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90, J. Natl. Cancer Inst., 91, 1940, 10.1093/jnci/91.22.1940

Kondo, 2002, Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein, Cancer Cell, 1, 237, 10.1016/S1535-6108(02)00043-0

Maloney, 2002, HSP90 as a new therapeutic target for cancer therapy: the story unfolds, Expert Opin. Biol. Ther., 2, 3, 10.1517/14712598.2.1.3

Maxwell, 1999, The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, Nature, 399, 271, 10.1038/20459

McLaughlin, 2002, Stimulation of the weak ATPase activity of human hsp90 by a client protein, J. Mol. Biol., 315, 787, 10.1006/jmbi.2001.5245

Minet, 1999, Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction, FEBS Lett., 460, 251, 10.1016/S0014-5793(99)01359-9

Neckers, 2002, Hsp90 inhibitors as novel cancer chemotherapeutic agents, Trends Mol. Med., 8, S55, 10.1016/S1471-4914(02)02316-X

Nimmanapalli, 2001, Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr- Abl-positive human leukemic blasts, Cancer Res., 61, 1799

Ohh, 2000, Ubiquitination of hypoxia-inducible factor requires direct binding to the B-domain of the von Hippel-Lindau protein, Nat. Cell Biol., 2, 423, 10.1038/35017054

Oppermann, 1981, Two cellular proteins that immunoprecipitate with the transforming protein of Rous sarcoma virus, Virology, 113, 736, 10.1016/0042-6822(81)90202-6

Panaretou, 1998, ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo, EMBO J., 17, 4829, 10.1093/emboj/17.16.4829

Panaretou, 2002, Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone Aha1, Mol. Cell, 10, 1307, 10.1016/S1097-2765(02)00785-2

Pegram, 1998, Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment, J. Clin. Oncol., 16, 2659, 10.1200/JCO.1998.16.8.2659

Prodromou, 1997, Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone, Cell, 90, 65, 10.1016/S0092-8674(00)80314-1

Scheibel, 1998, The Hsp90 complex–a super-chaperone machine as a novel drug target, Biochem. Pharmacol., 56, 675, 10.1016/S0006-2952(98)00120-8

Schneider, 1996, Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90, Proc. Natl. Acad. Sci. USA, 93, 14536, 10.1073/pnas.93.25.14536

Seizinger, 1988, Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma, Nature, 332, 268, 10.1038/332268a0

Sharma, 1998, Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol, Oncogene, 16, 2639, 10.1038/sj.onc.1201790

Shiotsu, 2000, Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex, Blood, 96, 2284, 10.1182/blood.V96.6.2284

Siligardi, 2002, Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37, J. Biol. Chem., 277, 20151, 10.1074/jbc.M201287200

Solit, 2002, 17-allylamino-17-demthoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts, Clin. Cancer Res., 8, 986

Stebbins, 1997, Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent, Cell, 89, 239, 10.1016/S0092-8674(00)80203-2

Whitesell, 1994, Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation, Proc. Natl. Acad. Sci. USA, 91, 8324, 10.1073/pnas.91.18.8324

Wiesener, 2001, Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas, Cancer Res., 61, 5215

Xu, 2001, Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90, J. Biol. Chem., 276, 3702, 10.1074/jbc.M006864200

Xu, 2002, The chaperone-dependent E3 ubiquitin ligase CHIP mediates a novel degradative pathway for c-ErbB2/Neu, Proc. Natl. Acad. Sci. USA, 99, 12847, 10.1073/pnas.202365899

Young, 2000, Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23, EMBO J., 19, 5930, 10.1093/emboj/19.21.5930